交易 CareDx Inc - CDNA 差價合約
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. It also has a collaborative research agreement with Eledon Pharmaceuticals, Inc. to use AlloSure for assessing the efficacy of Eledon''s investigational AT-1501 in the prevention of rejection in upcoming renal transplantation trials. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.最新股票文章

期貨是什麼?一文看懂期貨合約運作、種類與香港交易入門
期貨是什麼?本文拆解期貨合約組成、保證金計算與常見類型(股指、商品、加密貨幣),並詳解香港恒指期貨玩法、開戶流程及風險管理,新手必讀入門教學。
10:57, 16 6月 2026

ETF是什麼?一文讀懂交易所買賣基金的運作、種類與投資方法
ETF是什麼?本文深入解析交易所買賣基金的運作原理、主要類型(指數、債券、主題、槓桿反向)、投資費用及香港/美股熱門ETF清單,幫助新手快速開始ETF投資。
10:21, 16 6月 2026

港人實戰:如何佈局 SpaceX IPO 前後的交易節奏
SpaceX以750億美元完成歷史性IPO,估值1.77萬億美元。深度解析港股CFD交易策略、供應鏈映射與恒生指數聯動,助投資者理解太空經濟相關市場動態。資本面臨風險。
08:58, 16 6月 2026

SpaceX上市首日收漲19%——IPO後如何交易SpaceX SPCX差價合約
SpaceX(SPCX)於2026年6月12日在納斯達克首次上市,開盤報150美元,收盤報160.95美元,較135美元的IPO發行價上漲19.2%。
08:23, 16 6月 2026